Drug repurposing is the novel treatment option accelerating the drug discovery process through the identification of a novel clinical use for an already existing approved drug which minimizes the costs, risks and saves time when compared with invention of a new drug. Siddha polyherbal medicine Amukkara Chooranam (AMKC) constitutes seven herbal ingredients being used in the treatment of various other diseases like Gastric ulcer, Peripheral neuritis, Gonorrhoea, Asthma and Tuberculosis. In this, Withania somnifera, Zingiber officinale has antiviral activity that inhibits M protease and Spike protein prevents the entry and growth of COVID-19. Piper longum, Piper nigrum, Mesua ferrea, Syzigium aromaticum binds with M protease [MPro] and ACE2 receptors and Elletaria cardamomum binds with Nucleocapsid protein [N protein] thereby inhibiting the viral replication. The polyherbal synergism of AMKC enhances its efficacy over co morbid conditions also. From various research reports, ingredients of AMKC revealed anti-inflammatory, anti-viral, immuno enhancing properties can exhibit potential activities against COVID-19. This made reasonable grounds on drug repurposing of AMKC as a novel clinical use for COVID-19. In future, clinical trials to be conducted to induce drug discovery through drug repurposing initiatives. Hence this review is intended to repurpose and explore the comprehensive effects of polyherbal formulation AMKC as a therapeutic approach for the management of COVID-19.  

Share this :